NuvoGen Research (originally called NeoGen) is a company that focuses on developing new approaches and products for drug discovery, particularly in oncology. NuvoGen's most successful product is the ArrayPlate technology, a process for performing high throughput screening using patterns of gene expression as the readout. This allows screening for compounds that affect the transcription of a group of genes (directly or indirectly), while testing for affects on control genes at the same time. The ArrayPlate technology was sold to and forms the IP platform for a startup company called HTG, Inc. (High Throughput Genomics), started in 2001 and now publicly traded on NASDAQ. NuvoGen Research has since entered into a collaboraiton swth Lightsense Technologies Lightsense in order to develop biomedical applications of Lightsense's path-breaking technology platform for infrared sensing. In addition, NuvoGen is working with Lightsense to develop an electronic nose for using breath to diagnose several diseases sucah as COPD, Asthma, lung cancer, GI diseases, etc.
